BMS Caffeine Adjuvancy Study Acetaminophen-Only Arm Unnecessary – FDA
This article was originally published in The Tan Sheet
Executive Summary
An acetaminophen-only treatment arm in Bristol-Myers Squibb's planned clinical study on the efficacy of different caffeine doses in analgesic adjuvancy is unnecessary, FDA says in a recent letter
You may also be interested in...
Headache Pain Model Enough To Show AAC Combination’s Efficacy – BMS
Studying the efficacy of 500 mg aspirin/500 mg acetaminophen/130 mg caffeine in a tension headache pain model is sufficient to demonstrate the combination merits Category I status in the internal analgesic drug products tentative final monograph, according to Bristol-Myers Squibb
Headache Pain Model Enough To Show AAC Combination’s Efficacy – BMS
Studying the efficacy of 500 mg aspirin/500 mg acetaminophen/130 mg caffeine in a tension headache pain model is sufficient to demonstrate the combination merits Category I status in the internal analgesic drug products tentative final monograph, according to Bristol-Myers Squibb
Headache Pain Model Enough To Show AAC Combination’s Efficacy – BMS
Studying the efficacy of 500 mg aspirin/500 mg acetaminophen/130 mg caffeine in a tension headache pain model is sufficient to demonstrate the combination merits Category I status in the internal analgesic drug products tentative final monograph, according to Bristol-Myers Squibb